Revolutionizing Dialysis: Quanta Dialysis Technologies Secures $60M in Funding for Groundbreaking Device

Quanta Dialysis Technologies is thrilled to announce the successful closure of a $60 million funding round, a significant milestone in our mission to revolutionize kidney replacement therapy. As a pioneering force in the healthcare sector, Quanta is dedicated to making dialysis accessible to every patient, regardless of their location. Our flagship product, the Quanta Dialysis System, is not just groundbreaking but also the first and only FDA-cleared device capable of performing Intermittent Hemodialysis (IHD), Sustained Low-Efficiency Dialysis (SLED), and Continuous Renal Replacement Therapy (CRRT) including CVVHD and SCUF without the cumbersome need for bags. This compact device marries portability with high performance, offering clinical versatility that meets various patient needs. With its user-friendly interface and minimal maintenance requirements, our technology empowers providers to deliver high-quality care in diverse settings - from hospitals to home care environments. The funding will accelerate our growth, enabling us to enhance our R&D initiatives, expand our market presence, and continue our commitment to innovation in dialysis care. Furthermore, we are proud to share that Quanta Dialysis Technologies was honored with the 2022 MacRobert Award by the Royal Academy of Engineering, joining prestigious companies like Rolls-Royce and Raspberry Pi in recognition of our engineering excellence. As we look forward, this funding will propel us toward fulfilling our vision of transforming the landscape of dialysis therapy, bringing hope and improved quality of life to patients worldwide.